Abstract
Minimal residual disease after complete tumor resection (R0) and adjuvant treatment is the predominant cause of relapse and death. Combining clinic-pathologic and genetic characteristics as well as TNM staging can either accurately identify these minimal microscopic disease or molecules responsible for subsequent relapse. Based on the genome – (genomic clones) – phenotypic event (drug resistance, relapse) map, this article summarizes the potential and challenges for the development of prognostic and predictive biomarkers to predict individualized drug response and prevent early and late relapse.
(Citation: Gastric & Breast Cancer 2019; 14(1): 33-39)
|
